virus
abund
biolog
entiti
planet
estim
virus
earth
bacteriophag
breitbart
rohwer
human
infect
virus
throughout
evolutionari
histori
seem
like
virus
play
role
human
evolut
van
blerkom
virus
signific
caus
morbid
mortal
around
world
transmit
via
air
food
water
direct
contact
contamin
bodi
fluid
virus
enter
bodi
variou
site
includ
respiratori
enter
tract
aerosol
droplet
droplet
nuclei
rout
understand
epidemiolog
pathogenesi
viral
infect
host
immun
respons
infect
key
control
prevent
viral
diseas
develop
vaccin
determin
minimum
dose
viru
particl
initi
infect
term
minimum
infect
dose
mid
factor
influenc
dose
import
develop
risk
assess
model
field
food
water
treatment
implement
appropri
infect
control
strategi
prevent
viral
transmiss
healthcar
set
oblig
intracellular
parasit
virus
must
invad
host
cell
initi
infect
whether
cultur
tissu
bodi
host
infect
human
normal
requir
extens
viral
replic
order
detect
due
limit
sensit
diagnost
method
typic
direct
detect
infecti
progeni
virus
bodi
product
nasal
secret
blood
fece
host
respons
antibodi
product
use
monitor
viral
infect
experiment
infect
human
dose
viru
administ
usual
determin
cell
cultur
infect
assay
presenc
infecti
viru
detect
abil
caus
chang
cell
appear
even
cell
destruct
throughout
monolay
cell
cytopath
effect
restrict
region
monolay
plaqu
format
viral
dose
express
either
dilut
viru
suffici
caus
cytopath
effect
inocul
cultur
plaqueform
unit
pfu
ward
et
al
investig
mid
human
virus
typic
involv
experiment
administr
viru
use
dose
respons
data
determin
viral
concentr
requir
infect
popul
human
concentr
requir
infect
lesser
percentag
popul
sinc
determin
requir
larg
number
test
subject
achiev
statist
signific
valu
make
timeconsum
expens
process
human
mid
express
sinc
repres
viral
concentr
requir
infect
popul
follow
valu
alway
greater
minimum
dose
requir
caus
infect
ward
et
al
furthermor
sinc
titer
viru
use
challeng
volunt
often
express
actual
number
viru
particl
involv
infect
often
unknown
number
factor
may
influenc
viru
dose
respons
data
obtain
studi
experiment
infect
human
volunt
includ
host
factor
age
health
statu
previou
exposur
viru
pathogen
factor
virul
viral
strain
passag
cell
cultur
experiment
factor
rout
inocul
sensit
assay
use
determin
viral
dose
administ
sinc
mid
studi
typic
use
young
healthi
volunt
singl
laboratori
adapt
attenu
viru
strain
therefor
limit
valu
assess
hazard
wildtyp
strain
gener
popul
even
less
individu
particular
risk
factor
use
mathemat
model
extrapol
doserespons
experiment
data
extrem
low
exposur
level
combin
like
underestim
mid
use
express
mid
experiment
limit
outlin
reason
concept
mid
threshold
infect
occur
receiv
critic
consequ
notion
singl
pathogen
may
capabl
caus
infect
singlehit
model
steadili
gain
support
especi
relat
virus
haa
haa
et
al
teuni
havelaar
thorough
review
mid
human
virus
publish
sinc
articl
ward
et
al
publish
decad
ago
review
infecti
dose
report
major
human
respiratori
enter
virus
determin
experiment
infect
human
volunt
respiratori
gastrointestin
tract
two
import
portal
entri
virus
human
evan
larg
proport
viral
mid
studi
focus
respiratori
virus
ward
et
al
follow
interest
respiratori
virolog
speci
rhinovirus
coronavirus
enterovirus
adenovirus
parainfluenza
virus
respiratori
syncyti
viru
rsv
ad
influenza
measl
virus
caus
respiratori
tract
infect
restrict
patient
group
immunocompromis
member
famili
herpesvirus
includ
herp
simplex
cytomegaloviru
varicellazost
viru
epsteinbarr
viru
human
herp
viru
also
associ
respiratori
diseas
macki
list
pathogen
extend
recent
year
discoveri
novel
respiratori
virus
human
metapneumoviru
human
bocaviru
kahn
respiratori
virus
often
infect
airborn
rout
although
contact
contamin
surfac
also
import
mode
transmiss
brankston
et
al
couch
et
al
falsey
walsh
gwaltney
hendley
nica
et
al
antigen
distinct
virus
document
caus
sporad
epidem
respiratori
infect
infant
children
adult
macki
nichol
et
al
howev
divers
group
organ
small
number
distinct
famili
major
respiratori
rna
virus
belong
follow
famili
orthomyxovirida
includ
influenza
viru
paramyxovirida
includ
parainfluenza
viru
rsv
picornavirida
includ
rhinovirus
enterovirus
coxsackieviru
number
enterovirus
coronavirida
includ
human
coronaviru
hcov
sever
acut
respiratori
syndromeassoci
cov
sarscov
import
respiratori
dna
virus
belong
famili
adenovirida
parvovirida
herpesvirida
although
viral
respiratori
infect
classifi
caus
viru
gener
classifi
clinic
accord
syndrom
produc
eg
common
cold
bronchiol
pneumonia
croup
infect
respiratori
tissu
normal
initi
upper
respiratori
tract
also
site
virus
come
contact
immun
system
certain
respiratori
virus
rhinovirus
adenovirus
coronavirus
limit
infect
upper
respiratori
tract
caus
gener
selflimit
common
coldlik
ill
virus
howev
capabl
penetr
initi
defens
upper
respiratori
tract
caus
seriou
potenti
lifethreaten
lower
respiratori
tract
infect
virus
import
influenza
viru
rsv
parainfluenza
viru
type
caus
greatest
burden
respiratori
diseas
human
adair
experiment
human
infect
respiratori
virus
mainli
conduct
administr
viru
via
nasal
drop
aerosol
drop
promot
infect
upper
respiratori
tract
aerosol
allow
infect
upper
lower
region
tract
although
virus
discuss
section
enter
virus
coxsackievirus
adenovirus
known
infect
respiratori
intestin
tract
henc
includ
section
influenza
viru
infect
highli
contagi
respiratori
diseas
spread
easili
respons
consider
morbid
mortal
year
kawaoka
nicholson
et
al
influenza
caus
rna
viru
famili
orthomyxovirida
classifi
three
type
influenza
b
c
influenza
essenti
avian
virus
period
transmit
speci
includ
mammal
howev
virul
human
pathogen
among
three
influenza
type
caus
sever
diseas
furthermor
influenza
virus
compris
larg
varieti
antigen
distinct
subtyp
replic
asymptomat
intestin
bird
constitut
larg
reservoir
potenti
pandem
virus
hay
et
al
influenza
c
infect
human
anim
pig
guo
et
al
matsuzaki
et
al
influenza
b
almost
exclus
infect
human
hay
et
al
three
differ
mode
influenza
transmiss
identifi
droplet
airborn
droplet
nuclei
contact
transmiss
brankston
et
al
garner
nica
et
al
tellier
three
mode
respons
influenza
infect
remain
highli
controversi
brankston
et
al
tang
li
tellier
weber
stilianaki
numer
studi
report
infecti
dose
influenza
viru
human
volunt
tabl
use
variou
strain
influenza
b
viru
administ
either
nasal
drop
aerosol
result
studi
suggest
nasal
infecti
dose
influenza
viru
sever
order
magnitud
higher
airborn
infect
weber
stilianaki
mani
publish
infecti
dose
influenza
viru
come
studi
prophylact
therapeut
effect
variou
compound
investig
role
prevent
treat
experiment
induc
influenza
infect
human
volunt
studi
often
use
high
dose
viru
inocul
intranas
produc
diseas
mani
subject
possibl
exampl
approxim
influenza
b
strain
infect
inocul
subject
produc
ill
barroso
et
al
hayden
et
al
similar
dose
influenza
infect
inocul
subject
four
develop
ill
treanor
et
al
dose
influenza
infect
intranas
inocul
volunt
caus
ill
major
subject
brankston
et
al
murphi
et
al
studi
barroso
et
al
hayden
et
al
treanor
et
al
anoth
influenza
strain
infect
subject
caus
diseas
half
administ
intranas
dose
doyl
et
al
gentil
et
al
hayden
et
al
influenza
strain
infect
caus
diseas
half
inocul
popul
time
higher
dose
use
arroyo
et
al
dougla
et
al
infect
rate
strain
report
dose
caus
ill
subject
alnakib
et
al
two
influenza
strain
aunivers
aunivers
caus
ill
major
volunt
inocul
viru
deliv
nasopharynx
infect
inocul
subject
approxim
half
develop
influenza
symptom
bloomfield
et
al
togo
et
al
ten
time
higher
dose
strain
administ
similar
manner
nasopharynx
adult
male
volunt
show
higher
attack
rate
mann
et
al
human
influenza
viru
determin
mainli
attenu
vaccin
strain
use
dose
respons
data
attenu
coldadapt
reassort
influenza
viru
vaccin
commonli
deriv
mate
wildtyp
human
influenza
viru
coldadapt
ca
aann
bann
donor
avian
influenza
amallardnew
viru
determin
manner
alway
accur
represent
wildtyp
viru
may
virul
attenu
vaccin
strain
clement
et
al
snyder
et
al
exampl
snyder
et
al
report
dose
wildtyp
viru
infect
inocul
subject
becam
ill
wildtyp
viru
infect
volunt
caus
ill
half
avian
influenza
reassort
vaccin
respect
valu
compar
report
amallardnew
avian
human
reassort
viru
murphi
et
al
coldadapt
reassort
viru
wildtyp
strain
clement
et
al
avian
influenza
reassort
vaccin
report
respect
seroneg
volunt
sear
et
al
steinhoff
et
al
higher
avian
influenza
reassort
vaccin
seroneg
young
children
report
other
steinhoff
et
al
clement
et
al
determin
ca
viru
seroneg
adult
attenu
vaccin
deriv
aann
coldadapt
ca
donor
viru
wildtyp
viru
ten
one
hundr
infect
vaccin
respect
approxim
develop
immunolog
respons
dose
dose
wildtyp
infect
eight
volunt
caus
ill
half
ca
viru
slightli
less
infecti
seroneg
adult
ahong
ca
viru
person
vaccin
previous
infect
viru
murphi
et
al
two
separ
studi
vaccin
viru
crb
result
cross
influenza
bann
ca
viru
wildtyp
influenza
anderson
et
al
keitel
et
al
wildtyp
viru
less
volunt
given
wildtyp
viru
infect
keitel
et
al
compar
aann
coldadapt
reassort
viru
report
anoth
studi
seroneg
adult
volunt
sear
et
al
coldadapt
reassort
vaccin
report
steinhoff
et
al
sear
et
al
similar
determin
influenza
b
coldadapt
vaccin
deriv
influenza
bann
wildtyp
viru
influenza
bann
ca
viru
clement
et
al
coldadapt
influenza
ca
viru
low
seroneg
children
similar
avian
human
reassort
vaccin
steinhoff
et
al
aerosol
influenza
infect
document
mous
model
squirrel
monkey
model
human
volunt
alford
et
al
hood
snyder
et
al
asian
influenza
viru
report
administ
small
particl
aerosol
serum
antibodyfre
volunt
one
assum
retent
inhal
particl
alford
et
al
infecti
dose
compar
found
investig
strain
viru
given
mice
hood
nine
volunt
given
influenza
small
particl
aerosol
seroconvert
becam
ill
viru
suffici
caus
diseas
one
inocul
subject
moreov
low
level
serumneutr
antibodi
complet
effect
prevent
infect
ill
alford
et
al
ill
produc
studi
sever
equal
produc
previous
administr
strain
nasopharyng
knight
et
al
jao
et
al
report
low
influenza
deliv
nose
throat
healthi
suscept
volunt
ill
occur
inocul
subject
strain
infect
inocul
subject
dose
use
alford
et
al
hayden
et
al
report
intranas
inocul
approxim
influenza
viru
strain
caus
infect
suscept
adult
respect
compar
nasal
report
strain
dougla
et
al
dose
equin
influenza
aequi
viru
administ
five
volunt
nose
oropharynx
infect
individu
caus
ill
one
kasel
et
al
absenc
ill
remain
volunt
suspect
result
loss
viru
virul
result
egg
passag
viru
inoculum
loss
virul
human
influenza
strain
passag
chick
embryo
report
isaac
et
al
similar
observ
report
compar
dose
strain
use
inocul
human
volunt
found
infect
subject
caus
ill
alford
et
al
correl
valu
number
infecti
influenza
virion
howev
clear
ratio
number
virion
document
weber
stilianaki
use
realtim
quantit
pcr
van
elden
et
al
report
copi
viral
rna
influenza
copi
viral
rna
influenza
b
equal
respect
use
field
flow
fraction
multiangl
light
scatter
method
optim
analysi
size
distribut
total
particl
count
ratio
total
viru
count
rang
wei
et
al
valu
unusu
influenza
viru
prepar
bancroft
parslow
enami
et
al
evid
suggest
mani
natur
influenza
infect
occur
aerosol
rout
lower
respiratori
tract
may
prefer
site
initi
infect
atkinson
wein
tellier
patient
acut
infect
influenza
sneez
cough
respiratori
secret
contain
high
viru
titer
aerosol
viral
titer
measur
nasopharyng
wash
culmin
approxim
day
infect
reach
dougla
murphi
et
al
thought
virion
fit
aerosol
influenza
droplet
diamet
weber
stilianaki
consid
airborn
infecti
dose
influenza
approxim
viru
reach
respiratori
epithelium
atkinson
wein
show
influenza
could
easili
fit
one
aerosol
droplet
weber
stilianaki
summari
influenza
virus
caus
highli
contagi
respiratori
diseas
spread
easili
respons
consider
morbid
mortal
worldwid
three
type
influenza
influenza
virus
virul
human
pathogen
caus
sever
diseas
three
differ
mode
influenza
transmiss
identifi
droplet
airborn
droplet
nuclei
contact
transmiss
may
play
role
transmiss
infect
influenza
report
administ
small
particl
aerosol
serum
antibodyfre
volunt
studi
suggest
nasal
infecti
dose
influenza
viru
sever
order
magnitud
higher
airborn
infect
human
rhinovirus
jackson
muldoon
common
caus
acut
respiratori
tract
ill
global
includ
common
cold
makela
et
al
rotbart
hayden
infect
upper
lower
respiratori
tract
tissu
savolainen
et
al
major
factor
exacerb
asthma
johnston
et
al
nicholson
et
al
chronic
obstruct
pulmonari
diseas
johnston
virus
also
associ
sever
diseas
includ
otiti
media
arola
et
al
sinus
pitkaranta
et
al
pneumonia
abzug
et
al
human
rhinovirus
classifi
distinct
serotyp
offici
character
savolainen
et
al
rhinovirus
shed
infect
ill
individu
cate
et
al
mufson
et
al
rhinoviru
type
detect
nasopharyng
wash
experiment
infect
volunt
day
inocul
maxim
viru
titer
cate
et
al
jarjour
et
al
report
peak
nasal
viru
titer
rhinoviru
type
infect
asthmat
volunt
rhinovirus
transmit
via
contact
airborn
rout
couch
et
al
gwaltney
hendley
latter
transfer
infect
via
particl
aerosol
contact
transmiss
occur
physic
contact
infect
suscept
subject
indirectli
contamin
environ
surfac
experiment
infect
rhinovirus
conduct
anim
human
volunt
success
infect
chimpanze
type
gibbon
type
report
dick
dick
dick
pinto
haff
rhinovirus
normal
induc
ill
inocul
nasal
mucosa
drake
et
al
holm
et
al
perkin
et
al
peterson
et
al
produc
littl
ill
inocul
mouth
byno
et
al
hendley
et
al
infect
dose
rhinovirus
nose
eye
thought
compar
viru
infect
eye
appear
travel
eye
nasal
mucosa
via
tear
duct
byno
et
al
winther
et
al
byno
et
al
found
cold
could
produc
almost
readili
appli
viru
nasal
conjunctiv
swab
give
nasal
drop
volunt
throat
rel
resist
infect
alessio
et
al
report
rhinoviru
type
suscept
human
volunt
inocul
mouth
higher
nose
may
explain
difficulti
direct
oral
transmiss
rhinovirus
numer
studi
report
infect
dose
variou
rhinoviru
serotyp
human
volunt
tabl
dose
rang
administ
intranas
nasal
drop
via
aerosol
infect
inocul
subject
infecti
dose
rhinovirus
appear
lower
nose
compar
site
inocul
alessio
et
al
found
suscept
adult
volunt
inocul
rhinoviru
type
nose
insid
nare
tongu
outsid
nare
respect
addit
infecti
dose
rhinovirus
appear
also
lower
given
nasal
drop
aerosol
couch
et
al
report
differ
rhinoviru
type
strain
nih
administ
nasal
drop
aerosol
found
viru
aerosol
particl
inhal
dose
fail
infect
volunt
none
three
inhal
becam
infect
contrast
volunt
receiv
nasal
drop
becam
infect
although
none
becam
infect
lower
dose
lowest
report
valu
rhinovirus
infect
human
volunt
low
valu
rhinoviru
serotyp
respect
report
virus
administ
nasal
drop
antibodyfre
volunt
follow
two
passag
diploid
human
embryon
lung
cell
hendley
et
al
passag
rhinovirus
tissu
cultur
shown
reduc
virul
dougla
couch
report
three
passag
rhinoviru
type
human
embryon
lung
fibroblast
attenu
viru
strain
attenu
indic
decreas
infect
human
failur
produc
ill
decreas
frequenc
viru
shed
three
passag
viru
cell
rather
two
passag
increas
decreas
ill
rate
infect
volunt
presenc
serum
antibodi
rhinovirus
also
link
alter
infecti
dose
virus
decreas
frequenc
sever
ill
cate
et
al
hendley
et
al
rhinoviru
type
caus
ill
inocul
volunt
neutral
antibodi
titer
respect
mufson
et
al
rhinoviru
increas
antibodyfre
volunt
antibodi
titer
hendley
et
al
dose
rhinoviru
calcul
intranas
antibodyfre
volunt
infect
eight
inocul
subject
antibodi
titer
increas
volunt
antibodi
titer
hendley
et
al
summari
human
rhinovirus
common
caus
acut
respiratori
tract
ill
global
includ
common
cold
presenc
preexist
antibodi
well
passag
tissu
cultur
shown
reduc
virul
increas
decreas
ill
rate
infect
volunt
rhinoviru
shown
greater
infect
man
cultur
rhinoviru
infecti
given
nasal
droplet
aerosol
spray
lower
infecti
dose
nose
compar
site
inocul
mouth
coxsackievirus
extrem
small
huebner
et
al
quigley
singlestrand
rna
virus
first
report
dalldorf
sickl
member
famili
picornavirida
genu
enteroviru
also
includ
polioviru
virus
divid
group
group
b
base
earli
observ
pathogen
mice
carpent
boak
mani
coxsackieviru
serotyp
identifi
coxsackieviru
particular
use
experiment
infect
human
volunt
couch
et
al
spickard
et
al
although
classifi
enter
viru
cultur
rectal
swab
fece
natur
infect
individu
recoveri
pharynx
individu
common
johnson
et
al
coxsackieviru
shown
caus
respiratori
ill
natur
bloom
et
al
johnson
et
al
experiment
infect
couch
et
al
spickard
et
al
airborn
transmiss
coxsackieviru
also
report
couch
et
al
studi
antibodyfre
volunt
quarter
barrack
separ
center
doublewir
barrier
ten
volunt
one
side
inocul
viru
small
particl
aerosol
side
opposit
side
receiv
placebo
inocul
contact
men
two
side
prevent
contact
individu
outsid
barrack
minim
dose
viru
caus
infect
ten
inocul
volunt
ill
eight
remain
volunt
infect
coxsackieviru
studi
becam
ill
viru
recov
airborn
particl
cough
sneez
sampl
produc
inocul
volunt
level
sneez
sampl
cough
sampl
viru
also
recov
room
air
sampl
level
per
sampl
although
direct
correl
coxsackieviru
viru
particl
number
rare
determin
particl
ratio
viral
prepar
report
ward
et
al
couch
et
al
report
coxsackieviru
strain
passag
human
embryon
kidney
cell
administ
antibodyfre
volunt
particl
aerosol
two
infect
subject
fail
develop
ill
indic
ill
dose
nearli
previou
studi
spickard
et
al
antibodyfre
volunt
inocul
nasopharynx
coars
spray
drop
strain
becam
infect
eight
develop
upper
respiratori
diseas
viru
isol
frequent
throat
swab
infect
subject
week
studi
immunolog
statu
volunt
found
critic
determin
biolog
clinic
sequela
viral
administr
high
antibodi
titer
gave
resist
infect
none
volunt
develop
ill
viru
rare
recov
studi
also
report
subject
detect
antibodi
level
exhibit
milder
ill
less
viral
shed
inocul
coxsackieviru
couch
et
al
antibodyfre
volunt
inocul
coxsackieviru
strain
passag
twice
human
embryon
lung
fibroblast
via
particl
aerosol
approxim
nearli
infect
subject
develop
ill
couch
et
al
howev
aerosol
estim
base
inhal
dose
retain
henc
actual
valu
probabl
consider
less
estim
nevertheless
strain
viru
administ
antibodyfre
volunt
nasal
drop
decreas
calcul
five
seven
infect
subject
develop
ill
couch
et
al
result
demonstr
coxsackieviru
strain
passag
twice
cell
cultur
similar
strain
obtain
natur
occur
case
ill
passag
tissu
cultur
given
antibodyfre
volunt
result
similar
degre
infect
one
two
passag
couch
et
al
lang
et
al
report
inocul
antibodyfre
volunt
coxsackieviru
strain
passag
nine
time
primari
human
embryon
kidney
tissu
cultur
nasopharyng
rout
infect
subject
caus
ill
strain
passag
two
time
human
embryon
lung
tissu
administ
via
aerosol
dose
caus
ill
inocul
subject
intestin
administr
coxsackieviru
volunt
strongli
indic
intestin
primari
site
multipl
viru
human
adult
spickard
et
al
antibodyfre
volunt
given
coxsackieviru
coat
capsul
show
symptom
ill
viru
recov
rectal
orpharyng
specimen
neutral
antibodi
detect
week
feed
moreov
inocul
intestin
tract
volunt
larger
viru
dose
rehfuss
tube
entericco
capsul
result
ill
posit
throat
cultur
transient
intestin
infect
judg
cultur
stool
furthermor
detect
antibodi
day
inocul
subject
contrast
inocul
even
viru
respiratori
rout
caus
ill
volunt
follow
increas
neutral
antibodi
titer
recoveri
viru
pharynx
spickard
et
al
summari
although
classifi
enter
viru
coxsackieviru
import
caus
respiratori
ill
human
presenc
preexist
antibodi
shown
provid
protect
infect
viru
lead
milder
ill
less
viral
shed
unusu
passag
viru
twice
cell
cultur
affect
infect
coxscakieviru
infecti
given
nasal
droplet
particl
aerosol
respiratori
tract
show
poor
infect
gastrointestin
tract
adenovirus
group
nonenvelop
icosahedr
dna
virus
infect
broad
rang
vertebr
speci
davison
et
al
human
adenovirus
first
isol
earli
adenoid
tissu
hilleman
werner
row
et
al
highli
preval
human
popul
vogel
et
al
virus
caus
mainli
respiratori
gastrointestin
urinari
tract
eye
infect
occasion
lead
sever
diseas
affect
brain
heart
kidney
liver
especi
immunodefici
individu
goncalv
de
vri
kojaoghlanian
et
al
human
adenovirus
includ
genu
mastadenoviru
famili
adenovirida
compris
serotyp
goncalv
de
vri
earli
experiment
infect
volunt
adenovirus
bell
et
al
report
intranas
instil
adenovirus
type
swab
oropharynx
type
viru
produc
infect
demonstr
complementfix
antibodi
respons
occasion
minor
respiratori
ill
follow
inocul
could
attribut
infect
virus
hand
infect
ill
readili
produc
suscept
volunt
swab
lower
palpebr
conjunctiva
adenovirus
type
swab
virus
onto
conjunctiva
produc
higher
frequenc
conjunct
drop
viru
conjunctiv
fornix
studi
howev
quantifi
amount
viru
inocula
administ
volunt
experi
adenovirus
given
parenter
intramuscular
intracutan
intratumor
intraven
rout
hilleman
et
al
huebner
et
al
southam
et
al
present
evid
viral
infect
without
signific
ill
hilleman
et
al
howev
report
intramuscular
inject
volunt
pool
type
adenoviru
propag
tissu
cultur
human
embryo
intestin
infect
titer
caus
acut
respiratori
ill
chapronier
et
al
use
adenoviru
type
strain
apc
obtain
direct
passag
viru
cultur
human
adenoid
tissu
cultur
embryon
human
kidney
tissu
inocul
group
volunt
nasal
instil
inocul
type
viru
recov
four
antibiodyfre
volunt
half
develop
acut
pharyng
adenoviru
type
vaccin
report
dud
et
al
viru
strain
origin
isol
human
embryon
kidney
cell
throat
wash
patient
pharyng
strain
passag
four
time
human
embryon
kidney
cell
time
human
diploid
fibroblast
cultur
given
antibodyfre
volunt
entericco
capsul
viru
recov
stool
volunt
given
inoculum
none
given
lower
dose
dud
et
al
vaccin
volunt
strain
adenoviru
serotyp
isol
passag
sever
time
human
embryo
lung
diploid
fibroblast
cultur
caus
infect
accompani
increas
serumneutr
antibodi
level
serotyp
inocul
also
vari
degre
serotyp
viru
administ
volunt
ml
volum
materi
contain
spray
nose
nebul
selivanov
et
al
studi
mid
adenoviru
type
suggest
greater
dose
viru
requir
initi
infect
lower
intestin
tract
nasopharynx
lower
respiratori
tract
couch
et
al
gutekunst
et
al
studi
determin
smallest
adenoviru
type
dose
capabl
caus
infect
lower
intestin
tract
antibodyfre
volunt
given
viru
entericco
capsul
viru
given
manner
gutekunst
et
al
adenoviru
type
nasal
inocul
report
administ
small
particl
aerosol
dose
rang
caus
infect
ill
antibodyfre
volunt
inocul
aerosol
contrast
approxim
greater
dose
requir
caus
infect
suscept
volunt
inocul
nasal
drop
ill
occur
infrequ
couch
et
al
other
report
adenoviru
type
suspens
particl
ratio
administ
nasal
drop
antibodyfre
volunt
hamori
et
al
although
comprehens
infecti
dose
studi
report
adenoviru
type
given
larg
particl
aerosol
administr
rout
infect
six
antibodyfre
volunt
inocul
caus
ill
half
dose
given
via
small
aerosol
particl
caus
infect
ill
volunt
inocul
couch
et
al
studi
report
none
three
volunt
preexist
antibodi
titer
becam
infect
given
small
particl
aerosol
indic
presenc
serum
antibodi
may
caus
resist
infect
adenovirus
observ
also
report
other
bell
et
al
view
low
infecti
dose
adenoviru
type
given
small
particl
aerosol
attempt
made
character
inocula
term
number
viral
particl
necessari
caus
infect
couch
et
al
report
averag
viral
particl
aerosol
suffici
infect
suscept
volunt
nasal
drop
correspond
particl
author
note
take
account
portion
dose
taken
aerosol
exhal
two
third
viral
particl
singl
virion
infecti
dose
adenoviru
man
small
aerosol
exceedingli
small
summari
adenovirus
highli
preval
human
popul
compris
serotyp
caus
wide
rang
infect
presenc
preexist
antibodi
shown
protect
infect
adenoviru
type
dose
adenoviru
type
particl
report
infect
test
popul
studi
suggest
higher
dose
viru
requir
initi
infect
lower
intestin
tract
nasopharynx
lower
respiratori
tract
higher
dose
adenoviru
type
also
requir
caus
infect
administ
nasal
drop
administ
via
aerosol
novel
viru
recov
chimpanze
respiratori
symptom
design
chimpanze
coryza
agent
blount
et
al
ensu
decad
viru
renam
respiratori
syncyti
viru
rsv
reflect
giant
syncytia
form
tissu
cultur
epidemiolog
studi
clearli
establish
rsv
one
import
caus
sever
respiratori
tract
infect
infant
young
children
well
elderli
person
adult
underli
cardiopulmonari
diseas
falsey
walsh
hall
thompson
et
al
human
rsv
envelop
rna
viru
member
genu
pneumoviru
classifi
within
famili
paramyxovirida
viru
highli
contagi
believ
spread
primarili
larg
droplet
fomit
surviv
nonpor
surfac
skin
glove
mani
hour
henc
close
persontoperson
contact
contact
contamin
environment
surfac
autoinocul
requir
transmiss
falsey
walsh
rsv
shed
high
titer
infant
hospit
lower
respiratori
tract
diseas
day
mean
maxim
nasal
wash
titer
hall
et
al
adult
challeng
studi
volunt
excret
viru
day
peak
viru
titer
nasal
wash
lee
et
al
isol
rsv
passag
twice
rhesu
monkey
kidney
cell
administ
intraor
intranas
spray
adult
volunt
serum
antibodi
titer
higher
johnson
et
al
kravetz
et
al
dose
rang
caus
ill
volunt
inocul
addit
subject
shed
viru
develop
serolog
evid
infect
studi
suggest
viru
less
healthi
suscept
adult
volunt
inocul
intranas
dose
approxim
pfu
safetytest
clinic
isol
rsv
type
b
subject
becam
infect
determin
either
viral
shed
nasal
antigen
detect
rise
virusspecif
antibodi
titer
buchman
et
al
higgin
et
al
report
intranas
inocul
healthi
adult
volunt
bacteriolog
steril
tissu
cultur
fluid
strain
rsv
passag
contain
mckay
et
al
fail
produc
symptom
volunt
volunt
challeng
ml
fluid
nostril
show
laboratori
evid
infect
shown
viral
isol
andor
antibodi
rais
seven
develop
cold
higgin
et
al
number
studi
report
infecti
dose
rsv
safetytest
pool
viru
use
inocul
undergon
six
passag
human
embryon
kidney
cell
ten
passag
calf
kidney
cell
sever
addit
passag
bovin
embryon
kidney
cell
one
studi
mill
et
al
pfu
rsv
administ
intranas
drop
male
volunt
vari
level
serum
nasal
antibodi
infect
challeng
subject
produc
ill
interestingli
higher
dose
pfu
infect
volunt
caus
ill
six
discrep
infect
rate
thought
due
variat
sensit
assay
system
use
detect
viru
mill
et
al
noah
becker
nasal
inocul
healthi
nonsmok
young
adult
approxim
pfu
rsv
report
develop
clinic
symptom
upper
respiratori
infect
also
shed
viru
anoth
studi
lee
et
al
healthi
adult
subject
vari
antibodi
titer
inocul
intranas
challeng
viru
pool
rsv
strain
viru
clone
passag
sever
time
three
differ
cell
line
contain
dose
infect
challeng
subject
determin
viru
shed
rise
serum
antibodi
caus
ill
lower
dose
infect
inocul
volunt
shed
viru
rais
serum
antibodi
titer
relationship
prechalleng
serumneutr
antibodi
titer
volunt
infect
viru
establish
highest
infect
rate
achiev
use
high
inoculum
dose
subject
low
preinocul
serumneutr
antibodi
titer
observ
confirm
subject
preinocul
serumneutr
antibodi
titer
challeng
viru
becam
infect
lee
et
al
hall
et
al
investig
infect
rsv
strain
administ
nose
eye
mouth
adult
volunt
report
viru
may
infect
eye
nose
rout
appear
equal
sensit
dose
infect
three
four
volunt
given
either
eye
nose
one
eight
infect
via
mouth
inocul
thought
due
secondari
spread
viru
inoculum
proport
subject
infect
either
rout
dose
caus
infect
hid
wild
strain
rsv
like
would
less
report
multipli
passag
strain
second
passag
wild
strain
rsv
strain
infect
seroposit
adult
volunt
administ
dose
kravetz
et
al
trail
highli
attenu
rsv
vaccin
administ
intanas
seroposit
children
shown
dose
caus
infect
wright
et
al
howev
other
report
dose
rsv
attenu
vaccin
infect
seroposit
seroneg
infant
children
challeng
document
recoveri
viru
throat
andor
signific
rise
nasal
secret
antibodi
kim
et
al
moreov
one
three
seroneg
infant
administ
much
lower
dose
mutant
rsv
vaccin
becam
infect
parrott
et
al
result
suggest
like
dose
wild
rsv
requir
infect
infant
would
even
less
hall
et
al
summari
rsv
major
caus
sever
respiratori
tract
infect
infant
young
children
experiment
infect
studi
report
relationship
prechalleng
serumneutr
antibodi
titer
volunt
infect
viru
rsv
poor
infect
administ
via
mouth
shown
infect
eye
nose
rout
appear
equal
sensit
viru
low
dose
mutant
rsv
vaccin
caus
infect
infant
howev
rsv
infect
studi
reli
use
attenu
vaccin
strain
passag
sever
time
tissu
cultur
mid
wild
rsv
probabl
less
enter
virus
repres
wide
spectrum
viral
genera
invad
replic
mucosa
intestin
tract
virus
character
small
size
transmit
primarili
via
rout
import
agent
gastroenter
hepat
neurolog
diseas
ill
worldwid
bishop
kirkwood
sair
et
al
vasickova
et
al
enter
virus
spread
across
wide
rang
taxonom
genera
includ
dna
rna
virus
import
rna
enter
virus
includ
calicivirida
includ
noroviru
saproviru
picornavirida
includ
hepatoviru
hepat
viru
hav
enterovirus
poliovirus
coxsackievirus
echovirus
enterovirus
reovirida
includ
rotavirus
astrovirida
includ
astroviru
import
dna
enter
virus
includ
adenovirida
includ
adenovirus
parvovirida
includ
parvovirus
experiment
infect
studi
enter
virus
conduct
human
primarili
epidemiolog
import
virus
noroviru
poliovirus
echovirus
rotavirus
studi
discuss
follow
section
enter
virus
known
infect
respiratori
system
coxsackievirus
adenovirus
discuss
earlier
section
rotavirus
recogn
major
etiolog
agent
gastroenter
human
infant
young
children
young
speci
domest
laboratori
anim
cukor
blacklow
fulton
et
al
hoshino
et
al
kraft
sato
et
al
schoub
wood
safeti
medic
ethic
perform
live
viru
inocul
studi
suscept
human
volunt
children
experiment
rotaviru
infect
studi
perform
young
anim
simul
infect
infant
aich
et
al
report
inject
pfu
bovin
rotaviru
intestin
loop
old
calv
suffici
induc
consist
fluid
accumul
visibl
histolog
chang
intestin
villi
anoth
studi
ramig
old
mice
born
seroneg
dam
oral
inocul
pfu
number
anim
human
rotavirus
found
simian
rhesu
rrv
bovin
rotavirus
replic
caus
sever
diseas
canin
bovin
human
wa
rotavirus
either
replic
minim
caus
minim
diseas
fail
replic
caus
diseas
wa
dose
respons
studi
use
simian
viru
show
dose
low
pfu
induc
viru
replic
diseas
mice
although
intestin
viru
titer
sever
diseas
increas
parallel
viru
dose
earlier
studi
howev
report
although
inocul
old
mice
pfu
viru
strain
caus
ill
mice
dose
less
pfu
fail
produc
clinic
symptom
offit
et
al
howev
rotavirusspecif
immun
respons
observ
mice
inocul
dose
low
pfu
offit
et
al
miniatur
piglet
highli
suscept
infect
pfu
porcin
rotaviru
graham
et
al
payment
morin
report
intragastr
inocul
rotavirusesspecif
antibodyfre
piglet
low
dose
ou
strain
porcin
rotaviru
also
caus
infect
low
rotaviru
particl
equival
mpniu
probabl
number
infecti
unit
suffici
induc
infect
defin
develop
clinic
symptom
without
excret
viral
particl
stool
porcin
gastrointestin
tract
digest
physiolog
similar
man
pig
suggest
appropri
model
enter
infect
human
cliver
studi
henc
appropri
simul
infect
infant
earlier
investig
use
porcin
rotaviru
strain
found
lowest
dose
induc
clinic
ill
demonstr
viral
replic
highli
suscept
colostrum
depriv
caesarean
deriv
newborn
miniatur
piglet
pfu
graham
et
al
investig
also
found
tissu
culturepassag
viru
much
less
virul
observ
report
other
bohl
et
al
kapikian
et
al
interestingli
passag
rotaviru
primari
cell
increas
viru
infect
adapt
virus
growth
continu
cell
line
ward
et
al
one
human
volunt
rotaviru
infect
studi
conduct
ward
et
al
use
unpassag
safetytest
strain
cjn
human
rotaviru
obtain
stool
specimen
hospit
child
acut
gastroenter
adult
healthi
volunt
low
titer
serumneutr
antibodi
challeng
viru
ingest
ffu
focu
form
unit
viru
determin
dose
requir
produc
infect
without
ill
rotaviru
prepar
character
particleffu
ratio
although
safeti
concern
regard
studi
rais
graham
investig
reveal
viru
approxim
ffu
ffu
infect
nearli
suscept
adult
subject
dose
requir
caus
infect
compar
need
produc
ill
ward
et
al
rotavirusinfect
subject
shed
viru
particlesg
fecal
matter
bishop
flewett
gratacapcavalli
et
al
ward
et
al
viru
surviv
day
environment
condit
moe
shirley
littl
infecti
materi
could
therefor
contain
sever
time
mid
viru
contact
materi
repres
risk
infect
especi
suscept
individu
children
infant
risk
infect
contact
increas
contamin
dose
increas
microlit
infect
materi
still
repres
tini
drop
drop
may
contain
suffici
number
virus
caus
infect
less
obviou
import
health
hazard
consequ
asymptomat
viral
infect
less
suscept
host
ward
et
al
report
healthi
adult
human
volunt
experiment
infect
rotaviru
experienc
ill
mani
shed
viru
asymptomat
infect
individu
may
amplifi
viru
serv
viru
shedder
reservoir
infect
transmiss
highli
suscept
young
children
summari
rotavirus
recogn
major
caus
gastroenter
infant
young
children
shed
high
titer
even
infect
asymptomat
play
role
transmiss
unlik
mani
virus
passag
rotaviru
fecal
specimen
primari
cell
decreas
infect
increas
virul
low
dose
rotaviru
shown
caus
infect
less
ffu
strain
cjn
caus
infect
adult
volunt
howev
safeti
medic
ethic
experiment
infect
rotaviru
conduct
young
anim
adult
human
volunt
suscept
human
rotaviru
infect
infant
young
children
poliomyel
acut
central
nervou
system
viral
diseas
affect
motor
neuron
within
brainstem
spinal
cord
racaniello
caus
agent
diseas
poliomyel
viru
later
shorten
polioviru
identifi
landstein
popper
human
polioviru
small
singl
strand
rna
viru
member
genu
enteroviru
classifi
famili
picornavirida
three
serotyp
polioviru
caus
paralyt
diseas
transmiss
viru
thought
occur
close
person
contact
mostli
via
rout
poliovirus
excret
major
infect
previous
unvaccin
infant
young
children
week
durat
viral
shed
shorter
among
previous
vaccin
children
preexist
antibodi
infect
serotyp
previou
intestin
infect
homolog
polioviru
alexand
et
al
develop
live
attenu
vaccin
strain
poliovirus
provid
opportun
conduct
infecti
dose
studi
human
subject
includ
infant
children
appear
suscept
natur
infect
one
earliest
studi
field
conduct
koprowski
et
al
administ
sm
strain
polioviru
type
gelatin
capsul
suscept
human
volunt
antibodi
viru
sm
strain
attenu
rodent
adapt
follow
success
passag
viru
chick
embryo
monkey
kidney
tissu
cultur
result
tabl
show
calcul
dose
pfp
plaqueform
particl
infect
four
test
subject
determin
viru
shed
antibodi
respons
two
three
children
infect
dose
pfp
wherea
infect
occur
two
subject
receiv
pfp
studi
anoth
rodentadapt
attenu
polioviru
type
strain
tn
administ
subject
liquid
form
milk
suspens
laboratori
determin
infect
inocula
done
mice
noncytopathogen
charact
viru
strain
method
much
less
exact
employ
type
viru
result
tabl
reveal
individu
found
suscept
dose
small
mous
paralyt
dose
although
subject
infect
time
greater
dose
infect
occur
dose
approxim
unlik
sm
strain
tn
strain
rare
excret
infect
individu
flack
et
al
administ
two
live
attenu
strain
infant
less
month
old
oral
rout
subject
antibodi
acquir
mother
challeng
viru
sixteen
receiv
sm
type
viru
alon
concentr
rang
two
receiv
tn
type
concentr
infant
develop
activ
immun
inappar
alimentari
infect
demonstr
isol
viru
fece
strain
polioviru
use
sabin
infect
sever
volunt
dose
plotkin
et
al
report
oral
dose
type
fox
strain
polioviru
infect
seven
nine
infant
test
type
chat
strain
latter
studi
katz
plotkin
polioviru
type
fox
strain
administ
directli
stomach
gavag
tube
prematur
infant
deliveri
viru
directli
stomach
preclud
inaccuraci
due
loss
mouth
regurgit
lowest
dose
deliv
subject
infect
dose
infect
infant
respect
base
data
calcul
strain
predict
infect
prematur
infant
would
result
administr
author
point
calcul
infant
test
may
influenc
appar
resist
new
born
infant
dose
attenu
polioviru
warren
et
al
along
assumpt
virul
poliovirus
wild
enterovirus
least
infect
attenu
viru
use
author
conclud
contamin
small
quantiti
potenti
pathogen
viru
may
great
consequ
individu
even
proport
affect
individu
commun
remain
quit
low
katz
plotkin
minor
et
al
calcul
live
polioviru
type
sabin
vaccin
strain
administ
oral
old
infant
respect
although
small
number
subject
includ
studi
presenc
matern
antibodi
polioviru
type
appear
major
influenc
factor
estim
dose
sabin
vaccin
strain
administ
enter
capsul
three
adult
volunt
detect
antibodi
viru
infect
determin
viru
recoveri
rectal
swab
fece
rise
neutral
antibodi
titer
occur
subject
spickard
et
al
anoth
studi
horstmann
et
al
attenu
strain
polioviru
type
leon
sabin
et
al
administ
oral
milk
suspens
subject
possess
homotyp
antibodi
titer
either
larg
smaller
dose
individu
fed
larg
dose
becam
infect
secret
viru
throat
fece
rise
antibodi
titer
two
three
subject
fed
smaller
dose
becam
infect
one
natur
antibodi
acquir
type
antibodi
result
vaccin
formalin
vaccin
summari
polioviru
caus
agent
poliomyel
acut
diseas
central
nervou
system
develop
live
attenu
vaccin
strain
viru
provid
opportun
conduct
infecti
dose
studi
human
subject
includ
infant
children
variou
live
attenu
strain
use
dose
pfp
poliviru
type
sm
type
sabin
type
tn
type
fox
strain
respect
shown
caus
infect
least
inocul
subject
use
attenu
vaccin
strain
mid
wildtyp
poliovirus
unvaccin
infant
may
encount
real
life
may
lower
valu
nonbacteri
gastroenter
common
ill
frequent
occur
epidem
caul
b
sinc
first
recogn
agent
viral
gastroenter
adler
zickl
norovirus
frequent
caus
sporad
case
outbreak
acut
gastroenter
children
adult
blacklow
greenberg
caul
particularli
semiclos
environ
school
cruis
ship
hospit
residenti
home
green
et
al
lopman
et
al
vipond
virus
current
recogn
caus
almost
outbreak
nonbacteri
gastroenter
adult
mead
et
al
particularli
europ
australia
activ
surveil
lopman
et
al
us
alon
norovirus
estim
caus
infect
year
result
hospit
fatal
mead
et
al
evoc
call
winter
vomit
diseas
pathogen
name
chang
alongsid
improv
scientif
understand
first
call
norwalk
viru
norwalklik
viru
refer
outbreak
winter
vomit
diseas
elementari
school
norwalk
ohio
usa
adler
zickl
small
round
structur
viru
base
appear
electron
microscop
dolin
et
al
kapikian
et
al
intern
committe
taxonomi
virus
settl
noroviru
member
calicivirida
base
morpholog
phylogeni
noroviru
genom
singl
positivestrand
rna
enclos
nonenvelop
protein
coat
distinct
cupshap
depress
divers
among
norovirus
great
human
strain
classifi
three
genogroup
gi
gii
giv
least
genotyp
numer
subgroup
prototyp
norwalk
viru
design
ie
genogroup
genotyp
despit
divers
recent
year
strain
primarili
genogroup
ii
genotyp
respons
major
case
outbreak
glass
et
al
purpos
review
current
name
noroviru
use
refer
virus
refer
name
norwalk
viru
previou
public
noroviru
present
fece
vomitu
infect
peopl
shed
high
concentr
rout
atmar
et
al
experiment
infect
human
volunt
dose
rtpcr
unit
noroviru
prepar
liquid
fece
individu
particip
previou
noroviru
challeng
studi
graham
et
al
inocul
subject
becam
infect
met
predefin
definit
viral
gastroenter
noroviru
detect
fecal
sampl
median
week
week
viru
inocul
peak
viru
titer
measur
rtpcr
median
approxim
copiesg
fece
commonli
found
fecal
sampl
collect
resolut
symptom
one
sampl
viru
titer
copiesg
fece
chan
et
al
describ
patient
shed
noroviru
copiesg
fece
wherea
peak
fecal
viru
titer
observ
ozawa
et
al
infect
food
handler
lower
peak
median
titer
copiesg
fece
higher
would
expect
electron
microscop
studi
atmar
est
thornhil
et
al
noroviru
detect
vomitu
greenberg
et
al
infect
patient
vomit
viru
particl
assum
vomit
lobu
volum
ml
fact
particlesml
need
present
detect
electron
microscopi
caul
reid
et
al
distribut
viru
particl
aerosol
projectil
vomit
associ
noroviru
infect
suggest
airborn
inhal
rout
may
import
transmiss
infect
widespread
environment
contamin
result
noroviru
infect
viru
environment
robust
low
estim
infect
dose
particl
caul
also
conclud
addit
possibl
aerosol
inhal
hand
surfac
also
play
import
part
facilit
transfer
noroviru
infect
either
direct
transfer
transfer
food
eaten
without
cook
barker
et
al
investig
transfer
noroviru
contamin
fecal
materi
via
finger
cloth
handcontact
surfac
use
pcr
assay
report
noroviru
consist
transfer
via
contamin
finger
surfac
contamin
finger
could
sequenti
transfer
viru
seven
clean
surfac
decontamin
contamin
surfac
bleachdeterg
formul
without
prior
clean
suffici
prevent
transfer
noroviru
remain
fastidi
noncultivat
cell
cultur
readili
avail
anim
model
hamper
studi
pathogen
viru
howev
vitro
replic
system
viru
recent
describ
guix
et
al
katayama
et
al
use
avail
smallanim
model
noroviru
infect
murin
noroviru
liu
et
al
report
first
unequivoc
estim
mid
human
noroviru
experiment
inocul
group
mice
dose
pfu
note
dose
higher
pfu
initi
infect
major
mice
lower
dose
caus
infect
minor
inocul
mice
calcul
mid
pfu
intestin
infect
pfu
mesenter
lymph
node
infect
pfu
splenic
infect
minimum
dose
requir
seroconvers
found
pfu
liu
et
al
noroviruslik
particl
vlp
made
recombin
viru
capsid
protein
promis
vaccin
use
experiment
inocul
human
volunt
three
five
seroposit
volunt
given
oral
dose
noroviru
vlp
develop
rise
serum
antibodi
vlp
bicarbon
buffer
volunt
develop
rise
enzymelink
immunosorb
assay
elisa
antibodi
noroviru
protein
ball
et
al
tacket
et
al
investig
hormon
mucos
cellular
immun
respons
oral
noroviru
vlp
volunt
thirti
healthi
adult
volunt
receiv
oral
administ
noroviru
vlp
vaccin
develop
signific
rise
iga
antivlp
antibodysecret
cell
develop
mucos
antivlp
iga
nineti
percent
receiv
develop
rais
serum
antivlp
igg
neither
rate
seroconvers
geometr
mean
titer
increas
higher
dose
earlier
studi
tacket
et
al
volunt
ingest
noroviru
vlp
contain
transgen
potato
develop
immun
respons
kind
nineteen
develop
signific
increas
number
specif
iga
antibodysecret
cell
four
develop
specif
serum
igg
six
develop
specif
stool
iga
earli
studi
noroviru
infect
human
report
infect
could
experiment
transmit
volunt
administ
oral
stool
filtrat
diseas
patient
howev
studi
report
viru
dose
administ
titrat
infecti
viru
particl
inocula
possibl
dolin
et
al
show
stool
filtrat
affect
adult
origin
outbreak
norwalk
ohio
could
reproduc
diseas
administ
oral
healthi
adult
volunt
subsequ
studi
wyatt
et
al
filtrat
produc
ill
volunt
inocul
ill
character
primarili
vomit
andor
diarrhea
use
filtrat
keswick
et
al
success
infect
volunt
determin
rise
antibodi
titer
volunt
becam
ill
titer
inoculum
use
stool
filtrat
could
measur
howev
noroviru
viru
antigen
inoculum
detect
dilut
greenberg
et
al
dilut
keswick
et
al
studi
keswick
et
al
develop
rtpcr
detect
noroviru
rna
provid
altern
method
noroviru
enumer
number
experiment
infect
volunt
report
infecti
dose
viru
term
genom
copi
lindesmith
et
al
teuni
et
al
teuni
et
al
report
first
quantit
estim
noroviru
infect
human
volunt
use
rtpcr
dose
respons
model
primari
viru
inoculum
prepar
origin
noroviru
isol
dolin
et
al
use
challeng
volunt
secondari
inoculum
design
prepar
stool
sampl
infect
subject
first
experi
use
challeng
volunt
comparison
result
primari
secondari
inocula
show
passag
human
host
chang
noroviru
infect
viru
report
least
infecti
rotaviru
estim
averag
probabl
infect
singl
noroviru
particl
close
exceed
report
viru
studi
date
dose
respons
relat
aggreg
noroviru
inoculum
genom
copi
approxim
equival
aggreg
particl
dose
respons
relat
complet
disaggreg
viru
lead
estim
virus
teuni
et
al
unusu
pattern
immun
seen
noroviru
infect
preexist
serum
antibodi
noroviru
associ
protect
immun
person
higher
level
preexist
antibodi
fact
like
experi
symptomat
diseas
blacklow
et
al
johnson
et
al
studi
mador
et
al
graham
et
al
challeng
adult
volunt
inoculum
report
becam
infect
symptom
ill
report
proport
subject
infect
similar
without
preexist
antibodi
similarli
erdman
et
al
found
presenc
preexist
serum
iga
appear
associ
resist
infect
lessen
sever
symptom
number
studi
howev
demonstr
shortterm
immun
noroviru
dolin
et
al
wyatt
et
al
instanc
five
volunt
infect
noroviru
protect
subsequ
noroviru
challeng
week
later
wyatt
et
al
longterm
immun
noroviru
difficult
prove
volunt
initi
suscept
noroviru
infect
reinfect
month
latter
parrino
et
al
noroviru
challeng
studi
found
individu
suscept
noroviru
infect
diseas
symptom
blacklow
et
al
graham
et
al
parrino
et
al
observ
led
hypothesi
genet
resist
suscept
factor
miss
present
peopl
hutson
et
al
report
abo
histoblood
group
type
secretor
statu
two
genet
determin
factor
contribut
resist
suscept
noroviru
increas
risk
infect
associ
blood
group
noroviru
vlp
bound
gastroduoden
epitheli
cell
individu
secretor
se
cell
nonsecretor
observ
agreement
earlier
studi
lindesmith
et
al
report
se
volunt
challeng
dose
noroviru
inocula
rang
prcdetect
unit
develop
infect
noroviru
dose
level
se
volunt
becam
infect
howev
even
highest
dose
se
subject
becam
infect
suggest
exist
addit
mechan
prevent
noroviru
infect
none
volunt
becam
infect
challeng
dose
summari
noroviru
major
caus
outbreak
nonbacteri
gastroenter
worldwid
viru
present
fece
vomitu
infect
peopl
shed
high
concentr
rout
caus
consider
environment
contamin
viru
thought
low
infect
dose
particl
recent
work
suggest
viru
particl
unusu
pattern
immun
seen
noroviru
infect
number
studi
demonstr
shortterm
immun
viru
howev
longterm
immun
difficult
prove
preexist
serum
antibodi
associ
protect
immun
person
higher
level
preexist
antibodi
found
like
experi
symptomat
diseas
studi
shown
genet
factor
contribut
resist
suscept
noroviru
echovirus
enter
cytopathogen
human
orphan
virus
committe
echo
virus
small
nonenvelop
icosahedr
rna
virus
classifi
within
famili
picornavirida
genu
enteroviru
although
echovirus
organ
gastrointestin
tract
caus
wide
spectrum
diseas
sever
asept
mening
respiratori
infect
enceph
myocard
hill
wenner
outbreak
diseas
caus
echovirus
demonstr
abil
caus
signific
morbid
mortal
worldwid
hill
especi
among
infant
children
arnon
et
al
krou
et
al
ventura
et
al
number
studi
report
experiment
infect
echovirus
anim
pindak
clapper
vasilenko
et
al
vasilenko
atsev
use
human
volunt
buckland
et
al
kasel
et
al
philipson
saliba
et
al
schiff
et
al
strain
echoviru
uviru
close
resembl
modern
enterovirus
physiochem
properti
philipson
wesslen
success
transmit
via
nasal
rout
adult
volunt
passag
monkey
kidney
cell
shown
significantli
attenu
viru
compar
shortterm
passag
human
embryo
lung
cultur
buckland
et
al
preliminari
experi
viru
passag
time
monkey
kidney
tissu
fail
caus
ill
four
volunt
inocul
nasal
drop
howev
viru
recov
throat
swab
fece
three
four
challeng
subject
subsequ
test
nine
volunt
inocul
ml
uviru
cultur
fluid
contain
viru
passag
three
time
human
embryo
lung
cell
subject
infect
determin
viru
isol
throat
fece
rise
antibodi
titer
eight
develop
mild
definit
ill
day
inocul
eight
volunt
inocul
viru
passag
time
monkey
kidney
cell
although
subject
becam
infect
none
develop
definit
ill
viru
titer
throat
swab
fecal
specimen
infect
volunt
respect
buckland
et
al
saliba
et
al
report
infect
echoviru
type
man
experiment
infect
healthi
adult
volunt
either
high
low
dose
viru
volunt
vari
level
antibodi
titer
echoviru
includ
greater
sourc
challeng
viru
either
direct
nasal
secret
natur
infect
individu
titer
tissu
cultur
passag
dose
administ
via
oral
capsul
rest
administ
nasal
drop
notwithstand
presenc
antibodi
volunt
given
high
titer
viru
intranas
becam
infect
develop
signific
increas
serumneutr
antibodi
shed
viru
respiratori
enter
tract
low
titer
challeng
dose
infecti
subject
caus
ill
low
dose
inocula
howev
fail
elicit
signific
antibodi
respons
subject
immun
reinfect
upon
rechalleng
calcul
viru
either
respiratori
enter
rout
mid
man
estim
less
demonstr
echoviru
appear
equal
infect
respiratori
intestin
tract
take
nasal
secret
natur
acquir
echoviru
type
infect
viru
titer
nasal
discharg
infect
therefor
contain
mid
man
per
millilit
schiff
et
al
conduct
comprehens
studi
determin
mid
echoviru
type
human
volunt
studi
differ
previou
studi
use
enter
virus
use
unattenu
wild
viru
strain
administ
natur
rout
larg
number
suscept
individu
care
control
condit
isol
facil
echoviru
type
strain
isol
old
girl
erythema
infectiosum
passag
twice
primari
monkey
kidney
cell
safeti
test
prior
use
titer
viral
prepar
pfuml
determin
rd
human
rhabdomyosarcoma
cell
particlepfu
ratio
healthi
adult
male
volunt
serolog
evid
previou
echoviru
type
infect
administ
dose
rang
pfu
viru
ml
nonchlorin
water
volunt
develop
signific
ill
henc
infect
data
base
viral
shed
seroconvers
result
tabl
indic
echoviru
type
pfu
respect
previou
report
result
studi
less
sensit
plaqu
assay
cell
use
calcul
pfu
pfu
schiff
et
al
pfu
dose
viru
caus
infect
healthi
adult
detect
neutral
antibodi
caus
infect
previous
infect
individu
schiff
et
al
presenc
concentr
serum
antibodi
caus
signific
chang
rate
infect
durat
viral
shed
result
indic
previou
infect
echoviru
type
provid
last
protect
reinfect
although
studi
condit
infect
echoviru
type
much
less
suscept
healthi
adult
sensit
cultur
cell
fact
origin
viral
isol
passag
twice
primari
monkey
kidney
call
could
reduc
infect
man
furthermor
use
subject
infant
may
easili
infect
better
condit
infect
addit
food
buffer
stomach
acid
mayb
also
increas
infect
viru
man
ward
et
al
summari
echovirus
organ
gastrointestin
tract
caus
wide
spectrum
diseas
human
echoviru
found
equal
infecti
upper
respiratori
intestin
tract
exposur
echoviru
provid
last
immun
reinfect
presenc
concentr
serum
antibodi
caus
signific
chang
rate
echoviru
infect
durat
shed
similarli
main
effect
antibodi
decreas
viru
excret
shorten
ill
prevent
infect
echoviru
low
dose
echoviru
shown
caus
infect
least
volunt
test
less
echoviru
pfu
echoviru
infect
least
inocul
individu
hepat
formal
infecti
hepat
caus
hepat
viru
hav
small
nm
diamet
icosahedr
nonenvelop
singlestrand
rna
viru
belong
famili
picornavirida
member
genu
hepatoviru
holling
emerson
one
hav
serotyp
immun
infect
lifelong
lemon
et
al
viru
signific
caus
morbid
global
outbreak
report
world
gust
clinic
manifest
symptomat
hav
infect
vari
mild
anicter
ill
fulmin
hepat
liver
site
hav
replic
viru
mainli
excret
stool
dienstag
tjon
et
al
prolong
hav
fecal
excret
month
infect
presenc
blood
person
natur
experiment
infect
report
rosenblum
et
al
tjon
et
al
concentr
hav
rang
copiesml
serum
copiesml
stool
tjon
et
al
infecti
dose
hav
unknown
although
grabow
suggest
one
virion
caus
infect
infecti
dose
presum
order
virion
venter
et
al
hav
primarili
transmit
rout
either
persontoperson
contact
ingest
contamin
food
water
transmiss
also
occur
exposur
havcontamin
blood
blood
product
exposur
saliva
urin
fior
wide
varieti
vehicl
implic
hepat
outbreak
includ
recreat
drink
water
raw
milk
orang
juic
salad
cold
meat
hamburg
pasti
seafood
shellfish
dienstag
gust
venter
et
al
spread
viru
enhanc
environment
robust
hav
shown
resist
concentr
free
residu
chlorin
h
withstand
temperatur
h
freezethaw
low
rel
humid
day
ph
valu
low
ph
dienstag
venter
et
al
hav
shown
surviv
month
experiment
contamin
fresh
water
seawat
marin
sediment
wastewat
soil
oyster
venter
et
al
anim
studi
shown
stool
filtrat
patient
anim
infect
hav
inocul
oral
intraven
infecti
dienstag
et
al
leduc
et
al
purcel
et
al
surprisingli
viru
normal
transmit
rout
wildtyp
hav
shown
less
infecti
oral
compar
intraven
rout
tamarin
chimpanze
observ
alreadi
demonstr
young
adult
volunt
experiment
infect
live
attenu
strain
hav
sjogren
et
al
howev
experi
anim
determin
viru
titer
inocula
recent
studi
amado
et
al
use
ml
stool
suspens
hav
strain
recov
child
sporad
hepat
infect
cynomolgu
monkey
stool
suspens
titer
elisa
realtim
pcr
copiesml
administ
anim
intraven
none
anim
exhibit
clinic
manifest
relat
hepat
infect
show
histolog
biomed
sign
hepat
similar
result
obtain
earlier
investig
ml
stool
suspens
oral
administ
marmoset
appli
posterior
pharynx
anim
pinto
et
al
hornei
et
al
use
two
tissu
cultureadapt
variant
hav
strain
transmit
infect
guinea
pig
anim
inocul
viru
intraperiton
oral
develop
activ
asymptomat
infect
specif
histopatholog
chang
liver
voegt
first
report
transmiss
hav
volunt
feed
duoden
fluid
blood
obtain
patient
acut
phase
diseas
sinc
numer
attempt
infect
volunt
fece
serum
nasopharyng
wash
urin
infect
case
report
haven
studi
show
dose
rang
g
fece
ml
fecal
suspens
infect
patient
administ
via
oral
parenter
nasopharyng
rout
infecti
drake
et
al
haven
maccallum
bradley
krugman
ward
found
g
fecal
dose
patient
within
first
day
onset
jaundic
produc
diseas
oral
inocul
individu
respect
mid
estim
viru
pool
g
approxim
g
respect
cameron
describ
transmiss
hepat
six
volunt
intramuscular
inject
blood
obtain
patient
earli
diseas
work
drake
et
al
krugman
gile
show
small
volum
sera
ml
hepat
patient
suffici
initi
infect
inocul
oral
subcutan
intramuscularli
volunt
krugman
et
al
found
one
eleven
individu
given
intramuscular
inject
ml
serum
hepat
patient
acquir
anicter
hepat
studi
serum
prepar
calcul
ml
work
haven
b
show
hepat
jaundic
occur
volunt
subject
parenter
administr
ml
serum
infect
urin
nasopharyng
wash
incomplet
investig
contradictori
result
follow
administr
urin
volunt
oral
nasopharyng
rout
findlay
willcox
haven
maccallum
bradley
neef
stroke
voegt
result
test
nasopharyng
wash
neg
haven
neef
stroke
one
possibl
except
maccallum
bradley
evid
infecti
dose
hav
come
experi
use
hav
vaccin
sinc
late
import
featur
vaccin
appear
neutral
antibodi
hav
measur
elisa
viru
titer
express
term
elisa
unit
elu
studi
show
ml
intramuscular
dose
vaccin
prepar
strain
hav
contain
elu
hepat
antigen
seroconvers
rate
infant
de
et
al
children
findor
et
al
adult
andr
et
al
clemen
et
al
davidson
et
al
goubau
et
al
westblom
et
al
month
inocul
experi
dose
show
seroconvers
rate
month
inocul
vaccin
contain
elu
hepat
antigen
children
clemen
et
al
adult
goubau
et
al
dose
elu
seroconvert
adult
vaccin
respect
month
inocul
goubau
et
al
westblom
et
al
anoth
studi
sjogren
et
al
none
eight
volunt
receiv
dose
similar
vaccin
oral
antibodi
respons
volunt
receiv
similar
dose
intramuscular
rout
develop
antibodi
hepat
week
immun
dose
elu
vaccin
deriv
gbm
strain
hav
highli
immunogen
seroneg
adult
children
respect
fisch
et
al
lago
et
al
vaccin
deriv
live
attenu
f
variant
strain
hav
show
rate
seroconvers
within
week
elu
dose
inni
et
al
dose
elu
vaccin
seroconvert
adult
year
old
weight
kg
week
bertino
et
al
anoth
studi
similar
vaccin
seroconvert
recipi
respect
midthun
et
al
wang
et
al
report
approxim
children
administ
dose
vaccin
deriv
strain
hav
seroconvert
month
inocul
ren
et
al
show
dose
elu
vaccin
deriv
strain
hav
seroconvert
seroneg
adult
volunt
month
vaccin
summari
hav
caus
hepat
signific
caus
morbid
global
lifelong
immun
infect
viru
replic
liver
also
detect
high
concentr
stool
blood
infect
individu
hav
primarili
transmit
rout
either
persontoperson
contact
ingest
contamin
food
water
transmiss
also
occur
exposur
havcontamin
blood
blood
product
exposur
saliva
urin
viru
shown
less
infecti
oral
compar
intraven
rout
littl
quantit
data
mid
human
ml
stool
suspens
contain
rna
copiesml
hav
strain
administ
oral
intraven
anim
caus
infect
similarli
oral
dose
g
stool
intramuscular
dose
ml
blood
patient
hepat
infecti
volunt
vaccin
studi
use
attenu
hav
strain
show
seroconvers
achiev
intramuscular
inocul
dose
elu
vaccin
deriv
gbm
strain
hav
respect
review
studi
investig
infect
suscept
volunt
free
antibodi
administ
viru
report
howev
subject
either
preexist
antibodi
test
viru
immun
statu
known
presenc
preexist
antibodi
shown
affect
infecti
dose
protect
infect
mani
virus
includ
rhinoviru
coxsackieviru
rsv
adenoviru
howev
unusu
pattern
immun
diverg
trend
also
report
exposur
noroviru
echoviru
provid
last
immun
reinfect
presenc
concentr
serum
antibodi
caus
signific
chang
rate
echoviru
infect
durat
shed
similarli
presenc
preexist
serum
antibodi
noroviru
associ
protect
immun
person
higher
level
antibodi
found
like
experi
symptomat
diseas
studi
ethic
safeti
concern
surround
experiment
infect
human
volunt
live
wildtyp
virus
mani
studi
reli
use
anim
model
simul
infect
man
use
young
healthi
adult
human
volunt
result
investig
interpret
caution
alway
possibl
correl
data
gener
anim
studi
human
subject
design
human
studi
may
exclud
subject
suscept
viral
infect
instanc
experiment
infect
rotaviru
mainli
conduct
young
anim
adult
human
volunt
suscept
human
rotaviru
infect
infant
young
children
similarli
except
viral
infect
studi
conduct
healthi
individu
exclud
larg
popul
immunocompromis
diseas
individu
may
much
suscept
infect
addit
use
adult
healthi
volunt
may
accur
reflect
atrisk
popul
investig
commonli
use
labadapt
attenu
strain
potenti
use
live
vaccin
strain
passag
cell
cultur
less
virul
wildtyp
strain
infecti
dose
determin
use
attenu
strain
virus
may
accur
reflect
dose
requir
caus
infect
wildtyp
strain
may
significantli
lower
evid
studi
use
polio
vaccin
strain
determin
infecti
dose
children
infant
infant
children
may
suitabl
subject
test
infect
polioviru
vaccin
strain
attenu
less
virul
wildtyp
strain
unvaccin
infant
may
encount
real
life
worth
note
howev
viru
passag
cell
cultur
alway
associ
reduc
virul
report
demonstr
passag
cell
cultur
human
host
affect
virul
also
case
increas
viru
infect
coxsackieviru
strain
passag
twice
cell
cultur
infecti
unpassag
strain
obtain
natur
occur
case
ill
passag
noroviru
human
host
chang
viru
infect
passag
rotaviru
fecal
specimen
primari
cell
increas
virul
method
viru
administr
import
factor
consider
interpret
infecti
dose
virus
experiment
infect
volunt
particularli
relev
relat
respiratori
virus
abl
infect
upper
lower
respiratori
tract
region
virus
capabl
infect
respiratori
gastrointestin
tract
viral
dose
requir
caus
infect
vari
depend
viru
prefer
site
infect
viru
type
express
differ
viral
dose
requir
caus
infect
deliv
nasal
drop
promot
infect
upper
respiratori
tract
aerosol
allow
infect
upper
lower
region
tract
instanc
rhinoviru
coxsackieviru
infecti
given
nasal
droplet
aerosol
spray
adenoviru
influenza
requir
higher
viru
dose
caus
infect
administ
nasal
drop
administ
via
aerosol
virus
multipli
gastrointestin
respiratori
tract
coxsackieviru
adenoviru
higher
dose
virus
requir
initi
infect
gastrointestin
tract
compar
respiratori
tract
adenoviru
type
given
entericco
capsul
nasal
inocul
administ
small
particl
aerosol
similarli
coxsackieviru
deliv
nosopharynx
drop
intestin
either
entericco
capsul
rehfuss
tube
ill
induc
inocul
respiratori
tract
echoviru
howev
found
equal
infecti
upper
respiratori
intestin
tract
respiratori
virus
shed
high
titer
infect
individu
transmit
variou
rout
includ
contamin
environment
surfac
via
aerosol
virus
appear
infect
human
tissu
cultur
depend
deliveri
method
virus
rhinoviru
shown
greater
infect
man
cultur
enter
virus
also
shed
high
concentr
diseas
individu
caus
consider
environment
contamin
vomit
fece
infect
subject
transmit
mainli
via
rout
contact
contamin
surfac
eat
drink
contamin
materi
demonstr
experiment
viru
inocul
infect
shed
viru
may
occur
without
develop
ill
asymptomat
infect
import
health
hazard
infect
individu
sign
ill
may
amplifi
viru
serv
shedder
reservoir
diseas
transmiss
suscept
individu
mani
respiratori
enter
virus
minim
dose
caus
infect
human
report
literatur
tabl
appear
small
especi
highli
suscept
subject
infant
dose
less
influenza
viru
rhinoviru
adenoviru
report
infect
test
popul
similarli
low
dose
enter
virus
noroviru
rotaviru
echoviru
polioviru
caus
infect
least
volunt
test
case
noroviru
hav
possibl
singl
viru
particl
abl
initi
infect
howev
import
note
rel
investig
report
infect
dose
form
number
infect
particl
high
percentag
morpholog
ident
viral
particl
sampl
determin
electron
microscopi
typic
noninfecti
known
cell
system
fact
particleinfect
ratio
rare
equal
viru
assay
system
moreov
studi
determin
ratio
ratio
infect
also
worth
note
recent
data
regard
mid
human
virus
publish
mani
studi
review
articl
carri
mani
decad
ago
henc
report
infect
dose
human
virus
may
also
chang
date
studi
conduct
aid
improv
understand
viral
epidemiolog
microbiolog
infect
util
sensit
viru
assay
cultiv
quantif
techniqu
summari
mani
studi
conduct
provid
inform
mid
human
virus
howev
due
differ
epidemiolog
cultur
method
viru
differ
limit
experiment
procedur
estim
mid
interpret
caution
notwithstand
limit
mid
respiratori
enter
virus
appear
low
view
relat
like
host
characterist
atrisk
popul
interest
